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Relapsing fever due to Borrelia hermsii is characterized by recurrent bacteremia episodes. However, infection of B. hermsii, if not treated early, can spread to various
organs including the central nervous system (CNS). CNS disease manifestations are
commonly referred to as relapsing fever neuroborreliosis (RFNB). In the mouse model
of B. hermsii infection, we have previously shown that the development of RFNB
requires innate immune cells as well as T cells. Here, we found that prior to the onset
of RFNB, an increase in the systemic proinﬂammatory cytokine response followed by
sustained levels of IP-10 concurrent with the CNS disease phase. RNA sequencing analysis of the spinal cord tissue during the disease phase revealed an association of the
interleukin (IL)-17 signaling pathway in RFNB. To test a possible role for IL-17 in
RFNB, we compared B. hermsii infection in wild-type and IL-17A2/2 mice. Although
the onset of bacteremia and protective anti-B. hermsii antibody responses occurred similarly, the blood-brain barrier permeability, proinﬂammatory cytokine levels, immune
cell inﬁltration in the spinal cord, and RFNB manifestations were signiﬁcantly diminished in IL-17A2/2 mice compared to wild-type mice. Treatment of B. hermsii-infected
wild-type mice with anti-IL-17A antibody ameliorated the severity of spinal cord
inﬂammation, microglial cell activation, and RFNB. These data suggest that the IL-17
signaling pathway plays a major role in the pathogenesis of RFNB, and IL-17A blockade may be a therapeutic modality for controlling neuroborreliosis.

Signiﬁcance
Spirochetes of the genus Borrelia
can spread to various organs
including the central nervous
system. The neurological disease
manifestations in these bacterial
infections are commonly referred
as neuroborreliosis. Currently,
long-term antibiotic treatment is
the only the United States Food
and Drug Administrationapproved option for those
suffering from neuroborreliosis.
Using Borrelia hermsii infection in
mice, we have previously
established a relapsing fever
neuroborreliosis model. In this
model, we found that the
induction of interleukin (IL)-17A
signaling plays a major role in the
pathogenesis of relapsing fever
neuroborreliosis. We show that
anti-IL-17A antibody treatment
can ameliorate the pathology. Our
data suggest that IL-17A blockade
may be a therapeutic strategy for
controlling relapsing fever
neuroborreliosis.

neuroborreliosis j Borrelia hermsii j interleukin-17 j relapsing fever j inﬂammation

Neuroborreliosis is a disorder of the central nervous system (CNS) caused by a systemic
infection of spirochetes of the genus Borrelia including B. burgdorferi and B. hermsii
(1, 2). Infection with B. burgdorferi, an agent of Lyme disease, typically causes an
expanding skin lesion known as erythema migrans, which occurs at the site of the tick
bite (3). On the other hand, infection with B. hermsii, an agent of relapsing fever, is
characterized by recurrent bacteremic episodes (4, 5). If untreated, these spirochetes
can disseminate into several tissues, including the CNS, and can produce a wide range
of disease manifestations. In the case of Lyme neuroborreliosis (LNB), the common
clinical features are lymphocytic meningitis, cranial neuritis, or radiculoneuritis and
facial paralysis (6, 7). While most B. burgdorferi-infected patients recover with antibiotic treatment, ∼15% of infected individuals experience long-term neurological and
psychological symptoms that are unresponsive to antibiotics (8–10).
The ratio of CNS disease complications in relapsing fever patients is similar to that
in Lyme patients (11). The incidence and characteristics of relapsing fever neuroborreliosis (RFNB) in humans varies with the relapsing fever Borrelia species as well as the
immune status of the host (1). For example, in the case of B. recurrentis, the incidence
of CNS complications can be as high as 40% (4). Recently, B. miyamotoi was shown to
be responsible for the RFNB in a patient undergoing B cell depletion therapy for nonHodgkin lymphoma (12). In the murine model, B. turicatae was shown to invade the
CNS of immunodeﬁcient mice in a serotype-dependent manner and vestibular dysfunction is one of the prominent neurological manifestations (13, 14). The murine
models for neurological involvement during B. hermsii infections were characterized
mainly by the presence of bacteria in the CNS and meningitis in immunodeﬁcient
mice (15, 16). However, using the B. hermsii strain DAH, an isolate from a relapsing
fever patient, we found that immunocompetent wild-type C57BL/6 mice, when infected
with the strain DAH, exhibit a high incidence of CNS disease manifestations (17).
Furthermore, we found inﬁltration of many T cells into the lumbar region of the spinal
cord of B. hermsii-infected mice. Additionally, we found up-regulation of MHC II and
CD80 on inﬁltrating macrophages and resident microglial cells, suggesting roles for
T cell and innate immune cells in the pathogenesis of RFNB. Indeed, B. hermsii infection did not induce CNS disease manifestations in T cell-deﬁcient (TCR-βxδ/) mice,
although it resulted in bacteremia comparable to that in wild-type mice. Moreover, the
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inﬁltration of immune cells into the spinal cord of TCR-βxδ/
mice was reduced, and the resident microglial cells were not activated. Histopathological analysis of lumbar sections of the spinal
cord conﬁrmed severe inﬂammation in wild-type but not in
TCR-βxδ/ mice (17).
Immunopathogenesis is an important player in the infectioninduced neurological diseases (18, 19). Currently, long-term
antibiotic treatment remains the only US Food and Drug
Administration-approved option for those suffering from LNB
or RFNB (6). A better understanding of neuroborreliosis will
permit the identiﬁcation of new therapeutic targets for an
improved treatment. Interleukin 17 (IL-17) plays an important
role in several CNS-associated diseases (20) as well as autoimmune diseases (21). IL-17 was initially recognized to function
by activation of neutrophils and their migration to the inﬂammation site (22). For example, neutralization of IL-17 by antibody prevents the inﬁltration of neutrophils and protects against
ischemic stroke (23). Therefore, IL-17 is recognized as a potential therapeutic target for several CNS diseases (24). Indeed, several monoclonal antibodies against IL-17 or its receptor have
been evaluated in clinical studies of autoimmune diseases.
Components derived from pathogens can stimulate host cells
to produce IL-17 that interacts with vascular endothelial cells
to dissociate tight junctions and increase the permeability of
the blood-brain barrier (BBB). IL-17 can activate microglia and
astrocytes to produce inﬂammatory cytokines and chemokines
that can recruit inﬂammatory cells from the periphery into the
CNS thereby exacerbating CNS manifestations (25). Borrelia
can induce the production of IL-17 from the host cells in vitro
(26, 27). A correlation of increased levels of several cytokines
and chemokines including IL-17 were observed in individuals
experiencing LNB (28). Since we have an established B. hermsii
infection model of RFNB (17), in the present study we tested
the role of IL-17. We found that the lack of IL-17 or IL-17
blockade decreases the severity of RFNB, suggesting that IL-17
signaling can be a potential target for treating neuroborreliosis.
Results
Neuroborreliosis Is Associated with the Systemic Inflammation
in Borrelia hermsii-Infected Mice. To investigate the pathogene-

sis of RFNB, we infected the immunocompetent C57BL/6
mice with B. hermsii strain DAH (29) that is fully virulent in
wild-type mice (17). As expected, recurrent bacteremia was
developed, and B. hermsii-speciﬁc antibody responses were
induced (Fig. 1A and SI Appendix, Fig. S1 A–C). On day 8
post infection, mice began to show CNS complications, such as
tail weakness, followed by hind limb weakness and even paralysis, and the incidence of symptoms reached 100% (Fig. 1 B
and C) as reported previously (17). To further understand the
pathogenesis of RFNB, we measured a panel of cytokines and
chemokines associated with innate immune cells and T cells
and evaluated the temporal correlation of systemic inﬂammation in C57BL/6 mice infected with B. hermsii. Prior to the
induction of the CNS manifestations, high levels of the cytokine IL-6 as well as chemokines MIP-1β and MCP-1 were
induced, suggesting the activation of monocytes and macrophages during this phase (Fig. 1D). Interestingly, IP-10, known
to attract a variety of immune cells including T cells and dendritic cells, and to promote T cell adhesion to endothelial cells, is
induced throughout the B. hermsii infection phase. In the spinal
cords of infected animals, satellitosis was observed on 7 dpi and
14 dpi (Fig. 1E). The activation marker CD68 of inﬂammatory
cell was signiﬁcantly enhanced on 14 dpi as compared with
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that on 0 and 7 dpi (Fig. 1F). mRNA levels of IL-6, IL-8, and
TNF-α signiﬁcantly increased in the spinal cords on 14 dpi (SI
Appendix, Fig. S1D). Pathological changes were also observed
in spleens of B. hermsii-infected animals. On 7 dpi, megakaryocytes and inﬁltration of inﬂammatory cells were observed in the
spleens, followed by spleen congestion and inﬂux of inﬂammatory cells on 14 dpi (SI Appendix, Fig. S1E). Together, these
data suggest that systemic inﬂammation is associated with neurological inﬂammation and the CNS complications.
The IL-17 Signaling Pathway Is Associated with Neuroborreliosis.

To further explore the factors associated with the pathogenesis
of RFNB, we performed RNA sequencing (RNA-seq) analysis
of the spinal cords isolated from C57BL/6 mice on 14 d post
infection. Compared to uninfected mice, 1,525 genes were differentially expressed in the spinal cords of B. hermsii-infected
mice, of which 1,487 genes were up-regulated and 38 genes
were down-regulated (Fig. 2A). To validate the results from
the RNA-seq, we analyzed a subset of genes that are either
up-regulated or down-regulated (Fig. 2B) by real-time quantitative reverse transcription PCR (qRT-PCR) (Fig. 2C). Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway analysis of RNA-seq data showed that multiple innate immune and
inﬂammatory signaling pathways including IL-17 were activated in the spinal cord during B. hermsii-infection (Fig. 2D).
Gene Set Enrichment Analysis (GSEA) conﬁrmed signiﬁcant
enrichment of genes related to the IL-17 signaling pathway
(Fig. 2E). These data suggest that the IL-17 signaling pathway
is involved in the development of RFNB.
To directly test the involvement of IL-17 signaling in the
pathogenesis of RFNB, we compared B. hermsii infection in
mice sufﬁcient or deﬁcient in IL-17A (IL-17A/), the prototype member of the IL-17 cytokine family (24). We have previously shown that control of B. hermsii infection is mediated by
a T cell-independent immunoglobulin M (IgM) response (17).
Here we found that the levels of B. hermsii bacteremia as well
as the anti-B. hermsii response in IL-17A/ mice were comparable to those in wild-type mice (SI Appendix, Fig. S2 A and B),
indicating that the deﬁciency of IL-17A had no effect on
the severity of bacterial burden or antibody-mediated control.
However, the severity and the incidence of the CNS disease in
IL-17A/ mice were signiﬁcantly limited as compared with
those in the wild-type mice (Fig. 3 A and B).
We have previously shown an association of a massive inﬁltration of macrophages, B cells, CD4+ T cells, CD8+ T cells,
and natural killer (NK) cells with RFNB (17). We also found
that in the absence of T cells, neither inﬁltration nor inﬂammatory lesions are generated in the spinal cords of B. hermsiiinfected mice (17). Circulating IL-17 promotes BBB disruption
by altering expressions of tight junctions and cell-adhesion molecules on endothelial cells (30). Since the severity of the RFNB
is attenuated in IL-17 A/ mice, we investigated the effects of
IL-17 deﬁciency on the integrity of the blood-spinal cord barrier (BSCB) by analysis of the tight junction protein ZO-1 and
vascular marker CD31. We observed that ZO-1 localization in
the spinal cord was signiﬁcantly reduced in B. hermsii infected
wild-type but not IL-17A/ mice (Fig. 3 C and D and SI
Appendix, Fig. S2 C and D), suggesting that the lack of IL-17
signaling could protect BSCB integrity during B. hermsii infection. Analysis of proinﬂammatory cytokines in the spinal cords
showed that mRNA levels of IL-6, IL-8, and TNF-α were signiﬁcantly reduced in infected IL17A/ mice compared with
those in wild-type mice (Fig. 3E). Although satellitosis and
inﬁltration of inﬂammatory cells were observed in the spinal
pnas.org
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Fig. 1. Systemic inﬂammation and neuroborreliosis during B. hermsii infection. (A–C) Wild-type C57BL/6 mice (n = 10) were infected intraperitoneally (i.p.)
with 5 × 104 spirochetes of B. hermsii strain DAH. Blood was collected daily until day 21 for monitoring bacteremia (a representative plot from one mouse)
(A), clinical score (B), and incidence of CNS disease (C) (as described in Materials and Methods). (D) At the indicated time points, serum samples from infected
mice were harvested for measurement of inﬂammatory cytokines by Luminex. Data are represented as mean ± SD (n = 6 for each time point). (E and F)
Spinal cords of wild-type mice were collected on 0-, 7- and 14-d post infection (n = 6 for each time point) for histological analysis via H&E staining or immunohistochemistry staining. The representative pathological changes in spinal cords of H&E-stained specimens were indicated by arrows (E). The representative staining of CD68 was indicated by arrows (F). The activation of inﬂammatory cells was quantiﬁed as H-score (as described in Materials and Methods) (F). All
data are represented as mean or mean ± SD. Where applicable, data were analyzed via ordinary one-way ANOVA. *P < 0.05, **P < 0.01, and ***P < 0.001
and ns means no signiﬁcant difference (P ≥ 0.05). (Scale bars for E and F: 50 μm.)
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Fig. 2. Activation of inﬂammation-associated signal pathways during B. hermsii infection. Wild-type C57BL/6 mice were infected i.p. with 5 × 104 spirochetes
of B. hermsii and at days 0 and 14 post inoculation, spinal cords were harvested for RNA-seq analysis (n = 4 for each time point). (A) Volcano plot representing differential gene expression on 0- and 14-d post infection. A subset of differentially expressed genes in RNA-seq (B) was validated by qRT-PCR (C).
(D) Enrichment of regulatory pathways involved in B. hermsii infection was analyzed via KEGG. (E) Involvement of IL-17 signaling pathway during B. hermsii
infection was revealed by GSEA.
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Fig. 3. IL-17 signal plays a major role in the induction of relapsing fever neuroborreliosis. (A and B) Wild-type (WT) or IL-17A/ mice (n = 10 per group)
were infected i.p. with 5 × 104 B. hermsii strain DAH. The disease severity (A) and incidence (B) of the disease manifestations were monitored for 21 d.
(C) Wild-type (WT) (n = 6) or IL-17A/ mice (n = 4) were euthanized on day 7 post infection and spinal cords were collected for detection of ZO-1 (green)
and CD31 (red) by immunoﬂuorescence assay. (D) The ratio of positive area of ZO-1 over CD31 was calculated and each dot represents an individual mouse.
(E) On day 14 post infection, IL-6, IL-8, and TNF-α mRNA expression in the spinal cord of wild-type or IL-17A/ mice (n = 8 per group) was quantiﬁed by
qRT-PCR. (F and G) Spinal cords of wild-type and IL-17A/ (n = 8 per group) mice were analyzed for histological change as those in Fig. 1 E and F. All data
are represented as mean or mean ± SD. Where applicable, data were analyzed via two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001
and ns means no signiﬁcant difference (P ≥ 0.05). (Scale bars for C, F, and G: 50 μm.)
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cords of both wild-type and IL-17A/ mice (Fig. 3F), the
activation of inﬂammatory cells was signiﬁcantly lower in
IL-17A/ mice compared with that of wild-type mice (Fig. 3G).
These results demonstrate that IL-17 signaling plays a prominent
role in the pathogenesis of RFNB.
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Blocking IL-17A Attenuates CNS Disease Manifestations Induced
by B. hermsii Infection. Since IL-17A is involved in RFNB (Figs.

2 and 3), we speculated that IL-17A signaling might be a possible
therapeutic target for this disease. To test this, we intraperitoneally
administered anti-IL-17A antibody into wild-type mice and then
infected them with B. hermsii. This treatment did not affect the
development of bacteremia or the induction of B. hermsii-speciﬁc
IgG and IgM antibodies (SI Appendix, Fig. S3 A and B). However, the treatment with anti-IL-17A antibody signiﬁcantly
reduced the CNS disease manifestations and the incidence of this
CNS disease (Fig. 4 A and B). Furthermore, we found that antiIL-17A antibody treatment mitigated the histopathology of the
spinal cord in B. hermsii-infected mice (Fig. 4C). These ﬁndings
suggest that IL-17A could be a potential therapeutic target for
controlling RFNB.
To further explore the therapeutic mechanism of anti-IL-17
antibody, we ﬁrstly analyzed inﬂammation in the spinal cords
of infected animals. The inﬂammatory cytokines IL-6, IL-8,
and TNF-α were signiﬁcantly decreased in anti-IL-17A
antibody-treated animals as compared with those in untreated
animals (Fig. 4D). Strikingly, this decrease of inﬂammatory cytokine was not observed in the spleen of treated mice (SI Appendix,
Fig. S3C). We then investigated the cellular mechanism involved
in anti-IL-17 antibody treatment using immunoﬂuorescence analysis of the microglia marker Iba-1 and activation marker CD68
in the spinal cord. The percentage of Iba-1+CD68+ cells in the
spinal cord was signiﬁcantly reduced in mice treated with antiIL-17A antibody as well as in IL-17A/ mice as compared with
that in untreated but infected wild-type mice (Fig. 4 E and F),
indicating that blockade of IL-17 signaling prevented activation
of microglia in the CNS. These data suggest that targeting IL-17
could improve neurological complications by reducing the
inﬂammation in the CNS during RFNB.
Discussion
Complications of the CNS can occur in a wide range of infections, which may lead to permanent neurological deﬁcits in survivors (31). Neuroinﬂammation is a prominent factor for the
most neurological manifestations (32). The presence of spirochete in the CNS is one of important index for the induction
of neuroinﬂammation (1, 2). In the murine model of Lyme
disease, B. burgdorferi colonizes the dura mater and induces
inﬂammation in the central nervous system (33). However, in
the B. hermsii-infected neuroborreliosis, we were unable to detect
the spirochete by current methods possibly due to the limitation
of sensitivity and very low number of spirochetes. It is possible
that the RFNB could also be mediated by aseptic inﬂammation in
the CNS. In fact, aseptic meningitis is also described in relapsing
fever patients (34). Biomarkers for CNS disease are usually identiﬁed by analysis of cerebrospinal ﬂuid in clinical samples (27).
Borrelia is known to induce the production of IL-17 (26, 27).
Since we have established a murine model of CNS disease manifestations as well as pathology in immunocompetent mice
(17), in the present study, we were able to identify the impact
of IL-17 in the pathogenesis of RFNB.
IL-17, as an inﬂammatory and regulatory cytokine, has been
investigated in the physiological and pathological conditions
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for nearly 30 y (24). The effects of IL-17, a double-edged
sword, are beneﬁcial to wound healing, epithelial proliferation,
microbiota homeostasis, inﬂammation to combat infection, but
also involved in the pathogenesis of multiple autoimmune diseases, chronic degenerating diseases, chronic inﬂammation, and
diabetes-associated inﬂammation (35). These effects are determined by the amount of IL-17, status of its responding cells
and microenvironment. At present, there are three antibodies
against IL-17 being used in clinical therapy for autoimmune
diseases (36).
There are six members in the IL-17 family (IL-17A–IL-17F)
and each appears to have a distinct function (37). IL-17A is the
most studied immuno-regulatory inﬂammatory cytokine. In
this study, we blocked the IL-17A signaling by the administration of a neutralization antibody against IL-17A to attenuate
the disease severity (Fig. 4). The main cell types that produce
IL-17 are CD4+ T cells (Th17), followed by CD8+ T cells
(Tc17) and innate immune cells such as NK T cells, ILC3
cells, nTh17 cells (38), microglia (39), and neutrophils (40).
Furthermore, microglia and neutrophils also express receptors
for IL-17. Therefore, IL-17 secreted by microglia or neutrophils
can activate themselves via an autocrine loop to further produce
inﬂammatory cytokines IL-6, IL-1β, TNF-α and MIP-2 (39).
Here, we observed an increased number of Iba-1+CD68+ cells
in the spinal cord of mice with Borrelia-induced neurological
symptoms (Fig. 4), suggesting the activation of microglia.
Notably, treatment with anti-IL-17A antibody and a deﬁciency
of IL-17A blocked the activation of microglia (Fig. 4). However,
more studies are needed to understand the intrinsic or extrinsic
effects of IL-17 signaling on microglia.
CD4+ T cells signiﬁcantly contribute to pathogen-speciﬁc
adaptive immune responses via the production of effector cytokines (e.g., interferon [IFN]-γ and IL-17). For example, Th17
cells play critical roles in protective immunity against extracellular pathogens Klebsiella pneumoniae, Citrobacter rodentium,
and Candida albicans as well as intracellular bacteria like Listeria
monocytogenes, Salmonella enterica, and Mycobacterium tuberculosis
(41). However, Th17 cells are not expected to play a role in host
defense against B. hermsii, since we have shown that T cellindependent IgM responses mediated by B1b cells are sufﬁcient
for controlling B. hermsii infection (42, 43). Consistent with a
lack of a requirement for T cells in controlling B. hermsii, genetic
ablation of IL-17A or antibody-mediated depletion of IL-17A has
no impact on the protective antibody response against B. hermsii
(SI Appendix, Fig. S2 A and B). Since T cells are required for the
pathogenesis of RFNB (17), it is possible that they contribute to
disease progression by either producing IL-17 or other upstream
and downstream factors of the IL-17 signaling pathway. For example, B. hermsii infection results in production of high levels of systemic IL-6 prior to the RFNB induction phase (44) (Fig. 1D). It
is known that IL-6 is one of the prominent cytokines for promoting the development of Th17 cells via the STAT3 pathway (45).
It has been reported that IL-17 synergizes with IL-6 to enhance
the production of IL-6 by the astrocytes via a positive feedback
loop (46). We found that IL-6 transcripts were induced in the
spinal cord of B. hermsii-infected wild-type mice (SI Appendix,
Fig. S1D). This induction was signiﬁcantly reduced in the wildtype mice treated with anti-IL-17 antibody (Fig. 4D) or in mice
deﬁcient in the IL-17A (Figs. 3E and 4D). Interestingly, the
increase of IL-6 transcripts was not observed in the spleen during
the RFNB phase (SI Appendix, Fig. S3C). This suggests that
IL-6 may be synergizing with IL-17A in the astrocytes or other
cells of the CNS to generate an exaggerated inﬂammation by the
inﬁltrated T cells in the spinal cord, but not by those T cells
pnas.org
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Fig. 4. Blocking IL-17A ameliorates neuroborreliosis induced by B. hermsii infection. (A and B) Wild-type C57BL/6 mice without (n = 5) or with (n = 5) anti-IL-17A
antibody treatment or IL-17A/ (n = 6) were infected i.p. with 5 × 104 spirochetes of B. hermsii strain DAH. Clinical score (A) and incidence (B) of CNS manifestations were monitored until day 21 post infection. (C–F) Wild-type C57BL/6 mice without (n = 5) or with (n = 5) anti-IL-17A antibody treatment or IL-17A/ (n = 7)
were infected with 5 × 104 spirochetes of B. hermsii strain DAH, euthanized on 14 dpi, and spinal cords were harvested for histological examination of H&Estained specimens (C). mRNA levels of IL-6, IL-8, and TNF-α in spinal cords were determined via qRT-PCR (D). Immunoﬂuorescence staining of Iba-1 (green) and
CD68 (red) were performed (E). Stained sections were scanned on the 3D HISTECH system, followed by analysis of positively stained cells with the Indica laboratory software. The percentage of number of CD68+ cells to Iba-1+ cells were calculated and plotted (F). All data are represented as mean ± SD. Where applicable,
data were analyzed via two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, and ns means no signiﬁcant difference (P ≥ 0.05). (Scale bar for
C and E: 50 μm.)
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residing in the spleen. Follow-up studies are required to identify
the synergy between IL-17 and IL-6, the source of IL-6, and to
test whether IL-6 contributes to the auto ampliﬁcation loop in
the spinal cord during the pathogenesis of RFNB.
IL-17A/F/ mice show signiﬁcant variation of gut microbiota and are resistant to autoimmune diseases. Restoration of
gut microbes makes animals susceptible to the induction of
autoimmunity, suggesting that IL-17 could also induce the
neuroinﬂammation via the regulation of the microbiota (47).
In fact, 10–20% of broad-spectrum antibiotics treated Lyme
disease patients show post treatment Lyme disease syndrome in
the CNS, suggesting that the gut microbiota is involved in the
pathogenesis of the LNB (48).
In conclusion, this study demonstrates that IL-17 is involved
in the development of RFNB, and after treatment with IL-17A
neutralizing antibody, inﬂammation, and symptoms in CNS of
RFNB mice were signiﬁcantly improved. Therefore, targeting
the IL-17 signaling axis may be a promising approach for the
treatment of RFNB or possibly other neurological complications associated with the genus Borrelia.
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Materials and Methods
Mice and Infections. Mice were maintained in a speciﬁc pathogen-free facility
of the Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences,
and housed in individually ventilated cages with free access to food and water.
C57BL/6 mice were provided by Department of Experimental Animal of IMB.
IL-17A/ mice were on the C57BL/6 background, with age and sex matched
with wild-type C57BL/6 mice and they were provided via Materials Transfer
Agreement by the Center for Animal Disease Modeling, Institute of Biomedical
Sciences, Tokyo Institute of Technology, Japan. All animal procedures were
approved by the Institutional Animal Care and Use Committee of Institute of
Medical Biology, Chinese Academy of Medical Science (2015-10). The mice were
supplied with hardwood chips as bedding and housed in a temperaturecontrolled, air-conditioned room on a 12-h light-dark cycle. Eight- to 12-wk-old
male or female mice were injected intraperitoneally with 5 × 104 bacteria
(in 200 μL PBS) of a fully virulent B. hermsii strain DAH, a clinical isolate and
blood was sampled on the indicated day post infection from tail vein, and bacteremia was monitored by dark ﬁeld microscopy. The number of animals used in
each group was given in the ﬁgure legends.
Neurological manifestations in B. hermsii-infected mice were scored daily
using a well-established experimental autoimmune encephalomyelitis clinical
scoring protocol (49): 0, no observable signs; 1, completely limp tail and/or
weakness of one hind limb; 2, weakness of both hind limbs; 3, paralysis of
one hind limb; 4, paralysis of both hind limbs; and 5, death related with this
disease.
For histopathology and other analysis, mice were euthanized by CO2, transcardially perfused with PBS, and the spinal cord was harvested at the indicated
time points. For treatment with anti-IL-17A neutralizing antibody, a day before
B. hermsii infection, wild-type C57BL/6 mice were injected intraperitoneally with
anti-IL-17A neutralizing antibody (clone: eBioMM17F3, eBioscience) or IgG1
Isotype Control (P3.6.2.8.1, eBioscience) at the dosage of 100 μg for each
mouse and repeated treatment on the day 6 and 13 post B. hermsii infection.
ELISA for Borrelia hermsii-Specific IgM and IgG. B. hermsii-speciﬁc IgM
and IgG were determined as described previously (42, 43). Speciﬁc antibody
levels were interpreted as ng/μL equivalents using ELISA kits according to the
manufacturer’s instructions (Bethyl Laboratories).
Multiplex Cytokines Assay. The concentrations of cytokines and chemokines,
GM-CSF, IL-6, TNF-α, IL-2, IFN-γ, IL-1β, MIP-1β, IL-13, IL-4, IL-5, IL-17A, MCP-1,
IL-10, IL-12 (p70), and IP-10 in serum were determined using Mouse Cytokine/
Chemokine Magnetic Bead Panel (Millipore) via Luminex xMAP, according to
manufacturer’s instructions.
Histopathological Analysis. Tissues were ﬁxed in 10% neutral-buffered
formalin for approximately 2 d, followed by a series of standard tissue processing
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(dehydration, clearing, and wax inﬁltration) and embedded in parafﬁn wax. The
embedded spinal cord was transversely cut into 2-μm sections for hematoxylin
and eosin (H&E) staining and histopathological analysis.
Immunofluorescence Assay. The spinal cord was ﬁxed in 10% neutralbuffered formalin, and then embedded in parafﬁn for further analysis. Twomicrometer sections were prepared for immunoﬂuorescence (IF) staining.
Speciﬁc proteins in tissue sections were detected by incubations of properly
diluted primary antibodies (anti-ZO-1 Ab, anti-CD31 Ab, anti-CD68 Ab, and antiIba1 Ab all from ServiceBio). Following the addition of corresponding ﬂuorescentconjugated secondary antibodies, the stained sections were counterstained with
DAPI and then scanned on the 3D HISTECH system (3DHISTECH). The positive
staining was quantiﬁed by using the Indica Labs-Highplex FL (v3.1.0) module of
Halo software (v3.0.311.314).
Immunohistochemistry Staining. Immunohistochemistry staining of CD68
was performed on sections cut from the parafﬁn-embedded tissues using antiCD68 rabbit polyclonal antibody (Servicebio). Antigen retrieval was conducted by
microwaving slides in antigen retrieval buffer (pH 6.0) for 8 min at 800 W prior
to incubation with anti-CD68 antibody (1:400, Servicebio) at 4 °C overnight, followed by PBS wash and then incubation with HRP-conjugated goat anti-rabbit
IgG (1:200, Servicebio) for 50 min at room temperature. The reaction was visualized using the IHC Kit D (Servicebio). The stained sections were scanned on the
3D HISTECH system (3DHISTECH). The AIpathwell software (Servicebio) was used
to analyze the positive staining according to the manufacture’s instruction. The
quantiﬁcation of CD68 was conducted using modiﬁed H-scores ([f% of weak
stainingg × 1] + [f% of moderate stainingg × 2] + [f% of strong stainingg × 3])
as described (50), to determine the overall percentage of CD68 positivity across
the entire stained sample.
RNA-Seq Analysis. Total RNA was extracted from spinal cord tissues using the
TRIzol Plus RNA Puriﬁcation Kit (Invitrogen). The concentration and purity of total
RNA were determined by Qubit3.0 Flurometer (Life Technologies). RNA was
enriched and puriﬁed via magnetic beads with Oligo (dT). mRNAs were fragmented into short fractions by Fragmentation Buffer and used as templates to
synthesize the ﬁrst complementary DNA (cDNA) strands with random six bases
primers, and the second cDNA strand was synthesized by adding Buffer, dNTPs,
RNase H, and DNA Polymerase I. After elution and puriﬁcation, the doublestranded cDNA was treated with terminal repair, base A, and sequencing joint,
and then the target fragments were recovered by agarose gel electrophoresis for
PCR ampliﬁcation, to complete the preparation of the entire library. Qubit3.0
was used for preliminary quantiﬁcation of library that was then diluted to 1 ng/μL.
Agilent 2100 was used to detect the insert size of the library. After the insert
size met the expectation, Bio-Rad CFX 96 ﬂuorescence quantitative PCR instrument and Bio-Rad Kit iQ SYBR GRN were used for Q-PCR to accurately quantify
the effective concentration of the library (the effective concentration of the
library >10 nM) to ensure the quality of the library. Qualiﬁed libraries were
sequenced using Illumina platform. The sequencing strategy was PE150. RNA
analysis was performed using R Packages.

Total RNA was puriﬁed from spinal cord and spleen tissues via the
TRIzol Plus RNA Puriﬁcation Kit (Invitrogen), followed by the removal of genomic
DNA via gDNA Eraser (Perfect Real Time) (Takara) synthesis kit. Reverse transcription (RT) was carried out using PrimeScript RT reagent Kit (Takara). Brieﬂy, a total
of 500 ng RNA (from spinal cord) or 1 μg RNA (from spleen) was used for each
RT. Then qPCR was performed on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) with 2× TSINGKE Master qPCR Mix-SYBR (+UDG) (TSINGKE)
under the following conditions: 50 °C for 2 min, 95 °C for 2 min, and 40 cycles
at 95 °C for 15 s and 60 °C for 30 s. The copy number of target RNA was
calculated via the comparative Ct (ΔΔCt) method and normalized to the house
keeping gene GAPDH. The following primer pairs were used: Gapdh 50 -GAG
AGTGTTTCCTCGTCCCG-30 forward and 50 -ACTGTGCCGTTGAATTTGCC-30 reverse;
Cxcl10 50 -TCATTTTCTGCCTCATCCTGCT-30 forward and 50 -TGCGTGGCTTCA-CTCCAGTT30 reverse; Il1b 50 -TGAAGTTGACGGACCCCAAA-30 forward and 50 -GAAG-GTCC
ACGGGAAAGACA-30 reverse; Ccl12 50 -TAGCTACCACCATCAGTCCTC-30 forward and
50 -TTAACCCACTTCTCCTTGGGGT-30 reverse; Cyp4f18 50 -CACAGCCTCCCAAACGAAAC-30 forward and 50 -ACGGCTTCAGGAAACGGTAG-30 reverse; Lcn2 50 -AATGTC
ACC-TCCATCCTGGTC-30 forward and 50 -GGCGAACTGGTTGTAGTCCG-30 reverse;
qRT-PCR.
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C1ra 50 -AC- ATCACCACAAAAGGCGTG-30 forward and 50 -ACAGGGTTGACAGGTT
TCCC-30 reverse; Itga5 50 -AGGTGACAGGACTCAGCAAC-30 forward and 50 -AAACA
CTTGGCTTCAGGGC-A-30 reverse; Ptgs2 50 -GCATTCTTTGCCCAGCACTT-30 forward
and 50 -TCTCAGGGATGTG-AGGAGGG-30 reverse; Tnfaip3 50 -AGCTCAACTGGTGTCGTGAA-30 forward and 50 -CGA-GTGTCGTAGCAAAGTCCT-30 reverse; ApLNBBr 50 -TGG
TGTTCCGTTCCACAG-AC-30 forward and 50 -GGTCACTACAAGCACCACGA-30 reverse;
Car3 50 -TGGAGGAGTATGCGGACCTT-30 forward and 50 -AACACCTGGCTTCATGGGTG-30
reverse; Hsd11b1 50 -GGGAGCCCATG-TGGTATTGA-30 forward and 50 -GCGAGGTCTGA
GTGATGTGG-30 reverse; Calca 50 -GATC-AAGAGTCACCGCTTCG-30 forward and 50 -GG
GCTGCTTTCCAAGATTGA-C-30 reverse; Mc5r 50 -TGGGTCTCGTCAGCCTCTTA-30 forward
and 50 -GATGTACCTGTCCACCGCAA-30 reverse; IL6 50 -AGTTGCCTTCTTGGGACTGA-30
forward and 50 -CCTCCGACTTGTGAAGT-GGT-30 reverse; IL8 50 -CAGCTGCCTTAACCCC
ATCA-30 forward and 50 -CTTGAGAAGTCC-ATGGCGAAA-30 reverse; TNF-α 50 -GACA
AGGCTGCCCCGACTACG-30 forward and 50 -CTT-GGGGCAGGGGCTCTTGAC-30 reverse.

Data, Materials, and Software Availability. RNA-seq data have been
deposited in National Center for Biotechnology Information (NCBI) BioProject
(PRJNA751594) (51).
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